Eculizumab

Price	$1.8
Package	1KG

Min. Order:	1g
Supply Ability:	1KG/10KG/100KG
Update Time:	2024-10-22

Product Details

Product Name: Eculizumab	CAS No.: 219685-50-4
Min. Order: 1g	Purity: 98%
Supply Ability: 1KG/10KG/100KG	Release date: 2024/10/22

Amy 111 Email: amy@coreychem.com
Career Henan Chemical Co
Tel: +86-371-56618766
Fax: +86-371-86658258
Mob/Skype: +86-18317388371

Eculizumab Basic information

Product Name:	Eculizumab
Synonyms:	Alexion;Eculizumab;H5G1.1;H5G1.1Vhc H5G1.1vlc;Soliris;Unii-A3ulp0F556;ECULIZUMABUM;IMMunoglobulin,anti-(huMan coMpleMent C5 a-chain) (huMan-Mouse Monoclonal 5G1.1 heavy chain), disulfide withhuMan-Mouse Monoclonal 5G1.1 light chain, diMer (9CI)
CAS:	219685-50-4
MF:
MW:	0
EINECS:
Product Categories:
Mol File:	Mol File

Eculizumab Chemical Properties

Safety Information

MSDS Information

Eculizumab Usage And Synthesis

Description	Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC₅₀ ＝ 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9. Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).
Originator	Alexion (US)
Uses	Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.
Brand name	Soliris
General Description	Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Company Profile Introduction

Technology research and transfer of pilot screening, pilot scale-up and mass production solutions , for pharmaceutical intermediates, biologicals and fine chemicals (Not including inflammable , explosive , hazardous goods ) ; Market : Nano material , metal catalyst , raw material of cosmetics , pharmaceutical intermediates , chemicals , photoelectric material , import and export of technology and goods (For projects subject to approval according to law, business activities can be carried out only after approval by relevant departments ).